By Scientia Professor Vlado Perkovic

Journal articles

Singh AK; Carroll K; Perkovic V; Solomon S; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Więcek A; Blackorby A; Cizman B; Cobitz AR; Davies R; Dole J; Kler L; Meadowcroft AM; Zhu X; McMurray JJV, 2021, 'Daprodustat for the treatment of anemia in patients undergoing dialysis', New England Journal of Medicine, 385, pp. 2325 - 2335, http://dx.doi.org/10.1056/NEJMoa2113379

Sen T; Li J; Neuen BL; Arnott C; Neal B; Perkovic V; Mahaffey KW; Shaw W; Canovatchel W; Hansen MK; Heerspink HJL, 2021, 'Association between circulating gdf-15 and cardio-renal outcomes and effect of canagliflozin: Results from the canvas trial', Journal of the American Heart Association, 10, pp. e021661, http://dx.doi.org/10.1161/JAHA.121.021661

Feng KY; Li JW; Ianus J; de Zeeuw D; Fulcher GR; Pfeifer M; Matthews DR; Jardine MJ; Perkovic V; Neal B; Mahaffey KW, 2021, 'Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis', Diabetes, Obesity and Metabolism, 23, pp. 2707 - 2715, http://dx.doi.org/10.1111/dom.14525

Waijer SW; Gansevoort RT; Bakris GL; Correa-Rotter R; Hou FF; Kohan DE; Kitzman DW; Makino H; McMurray JJV; Perkovic V; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL, 2021, 'The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function A Post Hoc Analysis of the SONAR Randomized Trial', Clinical Journal of the American Society of Nephrology, 16, pp. 1824 - 1832, http://dx.doi.org/10.2215/CJN.07340521

Wong MG; Lv J; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Zhao M; Barbour S; Reich HN; Cattran D; Glassock R; Levin A; Jardine MJ; Wheeler DC; Woodward M; Billot L; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Zhang H; Perkovic V, 2021, 'The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics', American Journal of Nephrology, 52, pp. 827 - 836, http://dx.doi.org/10.1159/000519812

Heerspink HJL; Xie D; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Perkovic V; Rossing P; Parving HH; de Zeeuw D, 2021, 'Early response in albuminuria and long-term kidney protection during treatment with an endothelin receptor antagonist: A prespecified analysis from the SONAR trial', Journal of the American Society of Nephrology, 32, http://dx.doi.org/10.1681/ASN.2021030391

Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M, 2021, 'Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program', Diabetologia, 64, pp. 2402 - 2414, http://dx.doi.org/10.1007/s00125-021-05524-1

Neuen BL; Oshima M; Perkovic V; Arnott C; Bakris G; Cannon CP; Charytan DM; Jardine M; Levin A; Neal B; Pollock C; Wheeler DC; Mahaffey KW; Heerspink HJL, 2021, 'Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial', European Heart Journal, 42, pp. ehab724.2647, http://dx.doi.org/10.1093/eurheartj/ehab724.2647

Sen T; Li J; Neuen BL; Neal B; Arnott C; Parikh CR; Coca SG; Perkovic V; Mahaffey KW; Yavin Y; Rosenthal N; Hansen MK; Heerspink HJL, 2021, 'Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial', Diabetologia, 64, pp. 2147 - 2158, http://dx.doi.org/10.1007/s00125-021-05512-5

Rahimi K; Bidel Z; Nazarzadeh M; Copland E; Canoy D; Wamil M; Majert J; McManus R; Adler A; Agodoa L; Algra A; Asselbergs FW; Beckett NS; Berge E; Black H; Boersma E; Brouwers FPJ; Brown M; Brugts JJ; Bulpitt CJ; Byington RP; Cushman WC; Cutler J; Devereaux RB; Dwyer JP; Estacio R; Fagard R; Fox K; Fukui T; Gupta AK; Holman RR; Imai Y; Ishii M; Julius S; Kanno Y; Kjeldsen SE; Kostis J; Kuramoto K; Lanke J; Lewis E; Lewis JB; Lievre M; Lindholm LH; Lueders S; MacMahon S; Mancia G; Matsuzaki M; Mehlum MH; Nissen S; Ogawa H; Ogihara T; Ohkubo T; Palmer CR; Patel A; Pfeffer MA; Pitt B; Poulter NR; Rakugi H; Reboldi G; Reid C; Remuzzi G; Ruggenenti P; Saruta T; Schrader J; Schrier R; Sever P; Sleight P; Staessen JA; Suzuki H; Thijs L; Ueshima K; Umemoto S; van Gilst WH; Verdecchia P; Wachtell K; Whelton P; Wing L; Woodward M; Yui Y; Yusuf S; Zanchetti A; Zhang ZY; Anderson C; Baigent C; Brenner BM; Collins R; de Zeeuw D; Lubsen J; Malacco E; Neal B; Perkovic V; Rodgers A; Rothwell P; Salimi-Khorshidi G; Sundström J; Turnbull F; Viberti G; Wang J; Chalmers J; Davis BR, 2021, 'Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis', The Lancet, 398, pp. 1053 - 1064, http://dx.doi.org/10.1016/S0140-6736(21)01921-8

Kang A; Arnold R; Gallagher M; Snelling P; Green J; Fernando M; Kiernan MC; Hand S; Grimley K; Burman J; Heath A; Rogers K; Bhattacharya A; Smyth B; Bradbury T; Hawley C; Perkovic V; Krishnan AV; Jardine MJ, 2021, 'Effect of hemodiafiltration on the progression of neuropathy with kidney failure: A randomized controlled trial', Clinical Journal of the American Society of Nephrology, 16, pp. 1365 - 1375, http://dx.doi.org/10.2215/CJN.17151120

Wanner C; Cooper ME; Johansen OE; Toto R; Rosenstock J; McGuire DK; Kahn SE; Pfarr E; Schnaidt S; von Eynatten M; George JT; Gollop ND; Marx N; Alexander JH; Zinman B; Perkovic V, 2021, 'Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephroticrange proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial (Clinical Kidney Journal (sfaa225) DOI: 10.1093/ckj/sfaa225)', Clinical Kidney Journal, 14, pp. 2136, http://dx.doi.org/10.1093/ckj/sfab104

Mann JFE; Buse JB; Idorn T; Leiter LA; Pratley RE; Rasmussen S; Vilsbøll T; Wolthers B; Perkovic V, 2021, 'Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis', Diabetes, Obesity and Metabolism, 23, pp. 2058 - 2066, http://dx.doi.org/10.1111/dom.14443

Kalantar-Zadeh K; Jafar TH; Nitsch D; Neuen BL; Perkovic V, 2021, 'Chronic kidney disease', The Lancet, 398, pp. 786 - 802, http://dx.doi.org/10.1016/S0140-6736(21)00519-5

Yeung E; Bello AK; Levin A; Lunney M; Osman MA; Ye F; Ashuntantang G; Bellorin-Font E; Benghanem Gharbi M; Davison S; Ghnaimat M; Harden P; Jha V; Kalantar-Zadeh K; Kerr P; Klarenbach S; Kovesdy C; Luyckx V; Neuen B; O'Donoghue D; Ossareh S; Perl J; Ur Rashid H; Rondeau E; See E; Saad S; Sola L; Tchokhonelidze I; Tesar V; Tungsanga K; Turan Kazancioglu R; Wang AYM; Wiebe N; Yang CW; Zemchenkov A; Zhao M; Jager KJ; Caskey F; Perkovic V; Jindal K; Okpechi IG; Tonelli M; Feehally J; Harris DCH; Johnson D, 2021, 'Current status of health systems financing and oversight for end-stage kidney disease care: A cross-sectional global survey', BMJ Open, 11, http://dx.doi.org/10.1136/bmjopen-2020-047245

Wang KM; Li JW; Bhalla V; Jardine MJ; Neal B; de Zeeuw D; Fulcher G; Perkovic V; Mahaffey KW; Chang TI, 2021, 'Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program', Endocrinology, Diabetes and Metabolism, 4, pp. e00247, http://dx.doi.org/10.1002/edm2.247

Koomen JV; Stevens J; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan DE; Makino H; McMurray JJV; Parving HH; Perkovic V; Tobe SW; de Zeeuw D; Heerspink HJL, 2021, 'Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease', Clinical Pharmacology and Therapeutics, 109, pp. 1631 - 1638, http://dx.doi.org/10.1002/cpt.2143

Yi TW; Smyth B; Kang A; Cardoza K; Di Tanna GL; Arnott C; Pollock CA; Agarwal R; Bakris G; Cannon CP; De Zeeuw D; Heerspink HL; Levin A; Neal B; Wheeler DC; Zhang H; Zinman B; Mahaffey KW; Perkovic V; Jardine MJ, 2021, 'Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial', DIABETES, 70, http://dx.doi.org/10.2337/db21-129-LB

Liao J; Kang A; Xia C; Arnott C; Di Tanna GL; Krishnan AV; Pollock CA; Agarwal R; Bakris G; Heerspink HL; Levin A; De Zeeuw D; Neal B; Zhang H; Wheeler DC; Zinman B; Mahaffey KW; Perkovic V; Jardine MJ; Smyth B, 2021, 'The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial', DIABETES, 70, http://dx.doi.org/10.2337/db21-131-LB

Jun M; Harris K; Heerspink HJL; Badve SV; Jardine MJ; Harrap S; Hamet P; Marre M; Poulter N; Kotwal S; Gallagher M; Perkovic V; Chalmers J; Woodward M, 2021, 'Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial', Diabetes, Obesity and Metabolism, 23, pp. 1420 - 1425, http://dx.doi.org/10.1111/dom.14351

Perkovic V; Rovin B; Zhang H; Kashihara N; Maes B; Rizk D; Wang W; Meier M; Kollins D; Papachristofi O; Charney A; Barratt J, 2021, 'MO148A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNP023 IN PRIMARY IGA NEPHROPATHY PATIENTS', Nephrology Dialysis Transplantation, 36, http://dx.doi.org/10.1093/ndt/gfab092.0026

Perkovic V; Blackorby A; Cizman B; Carroll K; Cobitz A; Davies R; DiMino T; Jha V; Johansen K; Lopes R; Kler L; Macdougall I; McMurray J; Meadowcroft A; Obrador G; Solomon S; Taft L; Wanner C; Waikar SS; Wheeler D; Wiecek AJ; Singh A, 2021, 'MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS', Nephrology Dialysis Transplantation, 36, http://dx.doi.org/10.1093/ndt/gfab085.0022

Ye N; Jardine MJ; Oshima M; Hockham C; Heerspink HJL; Agarwal R; Bakris G; Schutte AE; Arnott C; Chang TI; Górriz JL; Cannon CP; Charytan DM; De Zeeuw D; Levin A; Mahaffey KW; Neal B; Pollock C; Wheeler DC; Luca Di Tanna G; Cheng H; Perkovic V; Neuen BL; Di Tanna GL, 2021, 'Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial', Circulation, 143, pp. 1735 - 1749, http://dx.doi.org/10.1161/CIRCULATIONAHA.120.048740

Zhou Z; Jardine MJ; Li Q; Neuen BL; Cannon CP; De Zeeuw D; Edwards R; Levin A; Mahaffey KW; Perkovic V; Neal B; Lindley RI; Guerrero RAA; Aizenberg D; Albisu JP; Alvarisqueta A; Bartolacci I; Berli MA; Bordonava A; Calella P; Cantero MC; Cartasegna LR; Cercos E; Coloma GC; Colombo H; Commendatore V; Cuadrado J; Cuneo CA; Cusumano AM; Douthat WG; Dran RD; Farias E; Fernandez MF; Finkelstein H; Fragale G; Fretes JO; Garcia NH; Gastaldi A; Gelersztein E; Glenny JA; Gonzalez JP; Del Carmen Gonzalez Colaso P; Goycoa C; Greloni GC; Guinsburg A; Hermida S; Juncos LI; Klyver MI; Kraft F; Krynski F; Lanchiotti PV; De La Fuente RAL; Marchetta N; Mele P; Nicolai S; Novoa PA; Orio SI; Otreras F; Oviedo A; Raffaele P; Resk JH; Rista L; Papini NR; Sala J; Santos JC; Schiavi LB; Sessa H; Casabella TS; Ulla MR; Valdez M; Vallejos A; Villarino A; Visco VE; Wassermann A; Zaidman CJ; Cheung NW; Droste C; Fraser I; Johnson D; Mah PM; Nicholls K; Packham D; Proietto J; Roberts A; Roger S; Tsang V; Raduan RA; Da Costa FAA; Amodeo C; Turatti LAA; Bregman R; Sanches FCC; Canani LH; Chacra AR; Borges JLC; Vêncio SAC; Da Silva Franco RJ; D'Avila D; De Souza Portes E; De Souza P; Phillips A, 2021, 'Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis', Stroke, 52, pp. 1545 - 1556, http://dx.doi.org/10.1161/STROKEAHA.120.031623

Wheeler DC; Weir M; Gogate J; Perkovic V; Mahaffey KW, 2021, 'EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE ALBUMINURIA: INTEGRATED ANALYSIS FROM THE CANVAS PROGRAM AND CREDENCE TRIAL', NEPHROLOGY DIALYSIS TRANSPLANTATION, 36, http://dx.doi.org/10.1093/ndt/gfab149.001

Weir MR; Slee A; Sun T; Balis D; Oh R; de Zeeuw D; Perkovic V, 2021, 'Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program', Clinical Kidney Journal, 14, pp. 1396 - 1402, http://dx.doi.org/10.1093/ckj/sfaa133

Adler A; Agodoa L; Algra A; Asselbergs FW; Beckett NS; Berge E; Black H; Brouwers FPJ; Brown M; Bulpitt CJ; Byington RP; Chalmers J; Cushman WC; Cutler J; Davis BR; Devereaux RB; Dwyer J; Estacio R; Fagard R; Fox K; Fukui T; Gupta AK; Holman RR; Imai Y; Ishii M; Julius S; Kanno Y; Kjeldsen SE; Kostis J; Kuramoto K; Lanke J; Lewis E; Lewis JB; Lievre M; Lindholm LH; Lueders S; MacMahon S; Mancia G; Matsuzaki M; Mehlum MH; Nissen S; Ogawa H; Ogihara T; Ohkubo T; Palmer CR; Patel A; Pepine CJ; Pfeffer MA; Pitt B; Poulter NR; Rakugi H; Reboldi G; Reid C; Remuzzi G; Ruggenenti P; Saruta T; Schrader J; Schrier R; Sever P; Sleight P; Staessen JA; Suzuki H; Thijs L; Ueshima K; Umemoto S; van Gilst WH; Verdecchia P; Wachtell K; Whelton P; Wing L; Woodward M; Yui Y; Yusuf S; Zanchetti A; Zhang ZY; Anderson C; Baigent C; Brenner BM; Collins R; de Zeeuw D; Lubsen J; Malacco E; Neal B; Perkovic V; Rodgers A; Rothwell P; Salimi-Khorshidi G; Sundström J; Turnbull F; Viberti G; Wang J; Ramakrishnan R, 2021, 'Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis', The Lancet, 397, pp. 1625 - 1636, http://dx.doi.org/10.1016/S0140-6736(21)00590-0

Yu J; Li J; Leaver PJ; Arnott C; Huffman MD; Udell JA; Perkovic V; Mahaffey KW; De Zeeuw D; Fulcher G; Matthews DR; Shaw W; Rosenthal N; Neal B; Figtree GA, 2021, 'Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial', Cardiovascular Research, 118, pp. 1103 - 1114, http://dx.doi.org/10.1093/cvr/cvab128

Copland E; Canoy D; Nazarzadeh M; Bidel Z; Ramakrishnan R; Woodward M; Chalmers J; Teo KK; Pepine CJ; Davis BR; Kjeldsen S; Sundström J; Rahimi K; Adler A; Agodoa L; Algra A; Asselbergs FW; Beckett N; Berge E; Black H; Brouwers FPJ; Brown M; Bulpitt CJ; Byington B; Cushman WC; Cutler J; Devereaux RB; Dwyer J; Estacio R; Fagard R; Fox K; Fukui T; Gupta AK; Holman RR; Imai Y; Ishii M; Julius S; Kanno Y; Kostis J; Kuramoto K; Lanke J; Lewis E; Lewis J; Lievre M; Lindholm LH; Lueders S; MacMahon S; Mancia G; Matsuzaki M; Mehlum MH; Nissen S; Ogawa H; Ogihara T; Ohkubo T; Palmer C; Patel A; Pfeffer M; Poulter NR; Rakugi H; Reboldi G; Reid C; Remuzzi G; Ruggenenti P; Saruta T; Schrader J; Schrier R; Sever P; Sleight P; Staessen JA; Suzuki H; Thijs L; Ueshima K; Umemoto S; van Gilst WH; Verdecchia P; Wachtell K; Whelton P; Wing L; Yui Y; Yusuf S; Zanchetti A; Zhang ZY; Anderson C; Baigent C; Brenner BM; Collins R; de Zeeuw D; Lubsen J; Malacco E; Neal B; Perkovic V; Pitt B; Rodgers A; Rothwell P; Salimi-Khorshidi G; Turnbull F; Viberti G; Wang J, 2021, 'Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis', The Lancet Oncology, 22, pp. 558 - 570, http://dx.doi.org/10.1016/S1470-2045(21)00033-4

Yu J; Arnott C; Neuen BL; Heersprink HL; Mahaffey KW; Cannon CP; Khan SS; Baldridge AS; Shah SJ; Huang Y; Li C; Figtree GA; Perkovic V; Jardine MJ; Neal B; Huffman MD, 2021, 'Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program', ESC Heart Failure, 8, pp. 1482 - 1493, http://dx.doi.org/10.1002/ehf2.13236

Oshima M; Jardine MJ; Agarwal R; Bakris G; Cannon CP; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Lim SK; Mahaffey KW; Neal B; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Perkovic V; Heerspink HJL, 2021, 'Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice', Kidney International, 99, pp. 999 - 1009, http://dx.doi.org/10.1016/j.kint.2020.10.042

Nataatmadja M; Krishnasamy R; Zuo L; Hong D; Smyth B; Jun M; de Zoysa JR; Howard K; Wang J; Lu C; Liu Z; Chan CT; Cass A; Perkovic V; Jardine M; Gray NA, 2021, 'Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis', Kidney International Reports, 6, pp. 1058 - 1065, http://dx.doi.org/10.1016/j.ekir.2021.01.020

Sarraju A; Li JW; Cannon CP; Chang TI; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Perkovic V; Jardine M; Mahaffey KW, 2021, 'Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial', American Heart Journal, 233, pp. 141 - 148, http://dx.doi.org/10.1016/j.ahj.2020.12.008

Htay H; Bello AK; Levin A; Lunney M; Osman MA; Ye F; Ashuntantang GE; Bellorin-Font E; Gharbi MB; Davison SN; Ghnaimat M; Harden P; Jha V; Kalantar-Zadeh K; Kerr PG; Klarenbach S; Kovesdy CP; Luyckx VA; Neuen B; O'Donoghue D; Ossareh S; Perl J; Rashid HU; Rondeau E; See EJ; Saad S; Sola L; Tchokhonelidze I; Tesar V; Tungsanga K; Kazancioglu RT; Yee-Moon Wang A; Yang CW; Zemchenkov A; Zhao MH; Jager KJ; Caskey FJ; Perkovic V; Jindal KK; Okpechi IG; Tonelli M; Harris DC; Johnson DW, 2021, 'Hemodialysis Use and Practice Patterns: An International Survey Study', American Journal of Kidney Diseases, 77, pp. 326 - 335.e1, http://dx.doi.org/10.1053/j.ajkd.2020.05.030

O'Hara DV; Parkhill TR; Badve SV; Jun M; Jardine MJ; Perkovic V, 2021, 'The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes', Diabetes, Obesity and Metabolism, 23, pp. 763 - 773, http://dx.doi.org/10.1111/dom.14281

Evans RDR; Smyth B; Levin A; Jha V; Wheeler DC; Jardine M; Perkovic V; Damster S; Malik C; de Zeeuw D; Hiemstra T, 2021, 'The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals', Kidney International, 99, pp. 551 - 554, http://dx.doi.org/10.1016/j.kint.2020.10.048

Yu J; Zhou Z; Mahaffey KW; Matthews DR; Neuen BL; Heerspink HJL; Jardine MJ; Li JW; Perkovic V; Neal B; Arnott C, 2021, 'An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials', International Journal of Cardiology, 324, pp. 165 - 172, http://dx.doi.org/10.1016/j.ijcard.2020.09.050

Oshima M; Hara A; Toyama T; Jun M; Pollock C; Jardine M; Harrap S; Poulter N; Cooper ME; Woodward M; Chalmers J; Perkovic V; Wong MG; Wada T, 2021, 'Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor', Kidney International Reports, 6, pp. 284 - 295, http://dx.doi.org/10.1016/j.ekir.2020.10.039

Koomen JV; Stevens J; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Parving HH; Perkovic V; Tobe SW; de Zeeuw D; Heerspink HJL, 2021, 'Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial', Diabetes, Obesity and Metabolism, 23, pp. 561 - 568, http://dx.doi.org/10.1111/dom.14252

Neuen BL; Arnott C; Perkovic V; Figtree G; de Zeeuw D; Fulcher G; Jun M; Jardine MJ; Zoungas S; Pollock C; Mahaffey KW; Neal B; Heerspink HJL, 2021, 'Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes', Diabetes, Obesity and Metabolism, 23, pp. 382 - 390, http://dx.doi.org/10.1111/dom.14226

Perkovic V; Koitka-Weber A; Cooper ME; Schernthaner G; Pfarr E; Woerle HJ; von Eynatten M; Wanner C, 2021, 'Choice of endpoint in kidney outcome trials: Considerations from the EMPA-REG OUTCOME^VR trial', Nephrology Dialysis Transplantation, 35, pp. 2103 - 2111, http://dx.doi.org/10.1093/NDT/GFZ179

Wanner C; Cooper ME; Johansen OE; Toto R; Rosenstock J; McGuire DK; Kahn SE; Pfarr E; Schnaidt S; Von Eynatten M; George JT; Gollop ND; Marx N; Alexander JH; Zinman B; Perkovic V, 2021, 'Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: The CARMELINA randomized controlled trial', Clinical Kidney Journal, 14, pp. 226 - 236, http://dx.doi.org/10.1093/ckj/sfaa225

Kotwal S; Perkovic V, 2021, 'Forever starts now: Effects of glucose-lowering therapies on acute kidney injury', Clinical Journal of the American Society of Nephrology, 16, pp. 6 - 8, http://dx.doi.org/10.2215/CJN.18141120

Jardine M; Zhou Z; Lambers Heerspink HJ; Hockham C; Li Q; Agarwal R; Bakris GL; Cannon CP; Charytan DM; Greene T; Levin A; Li JW; Neuen BL; Neal B; Oh R; Oshima M; Pollock C; Wheeler DC; de Zeeuw D; Zhang H; Zinman B; Mahaffey KW; Perkovic V, 2021, 'Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria a credence secondary analysis', Clinical Journal of the American Society of Nephrology, 16, pp. 384 - 395, http://dx.doi.org/10.2215/CJN.15260920

Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Blais J; Li Q; Jardine MJ; Perkovic V; Wheeler DC, 2021, 'Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program', American Journal of Kidney Diseases, 77, pp. 23 - 34.e1, http://dx.doi.org/10.1053/j.ajkd.2020.06.018

Li C; Zhou Z; Neuen BL; Yu J; Huang Y; Young T; Li J; Li L; Perkovic V; Jardine MJ; Keay L; Markoulli M; Rosenthal N; Capuano G; Yavin Y; Neal B; Arnott C, 2021, 'Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis', Diabetes, Obesity and Metabolism, 23, pp. 252 - 257, http://dx.doi.org/10.1111/dom.14197

Neuen BL; Jardine MJ; Perkovic V, 2021, 'Sodium-glucose cotransporter 2 inhibition: Which patient with chronic kidney disease should be treated in the future?', Nephrology Dialysis Transplantation, 35, pp. I48 - I55, http://dx.doi.org/10.1093/NDT/GFZ252

Singh AK; Carroll K; Perkovic V; Solomon SD; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Blackorby A; Cizman B; Cobitz AR; Davies R; Dimino TL; Dole JF; Kler L; Meadowcroft AM; Taft L; Zhu X; McMurray J, 2021, 'ASCEND Program: Efficacy and Safety from ASCEND-D and -ND and Overall MACE Finding', Journal of the American Society of Nephrology, 32, pp. B2 - B3, http://dx.doi.org/10.1681/asn.20213210s1b2c

Darshi M; Tefera E; Gao B; Weidner-Wells M; Reilly DF; Coorey C; Tang O; Yang J; Neal B; Arnott CG; Mahaffey KW; Perkovic V; Hansen MK; Ferrannini E; Figtree G, 2021, 'Circulating Metabolites to Predict Renal Outcomes in CANVAS Type 2 Diabetes Mellitus Population', Journal of the American Society of Nephrology, 32, pp. 47 - 47, http://dx.doi.org/10.1681/asn.20213210s147a

Yu J; Arnott C; Neuen BL; Heersprink HL; Mahaffey KW; Cannon CP; Khan SS; Baldridge AS; Shah SJ; Huang Y; Li C; Figtree GA; Perkovic V; Jardine MJ; Neal B; Huffman MD, 2021, 'Corrigendum', ESC Heart Failure, 8, pp. 3447 - 3447, http://dx.doi.org/10.1002/ehf2.13408

Back to profile page